Wall Street Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Wall Street Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$219K	Buy	440 +75	+21%	+$33.2K	0.12%	113
2026 Q1	$163K	Sell	365 -96	-21%	-$44.8K	0.1%	125
2025 Q4	$209K	Buy	+461	New	+$199K	0.15%	93

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

FAF

Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

Wall Street Financial Group's VRTX Position: Q2 2026 in Review

Wall Street Financial Group increased its Vertex Pharmaceuticals (VRTX) stake by 21% in Q2 2026, buying an estimated $33.2K and bringing the position to 440 shares worth $219K. The position accounts for 0.12% of the portfolio, ranked #113.

Wall Street Financial Group first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 650 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Wall Street Financial Group held 440 shares of Vertex Pharmaceuticals worth $219K as of Q2 2026.
Wall Street Financial Group bought 75 Vertex Pharmaceuticals shares in Q2 2026, an estimated $33.2K.
Vertex Pharmaceuticals made up 0.12% of Wall Street Financial Group's portfolio in Q2 2026, its #113 holding.
Wall Street Financial Group first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
650 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Wall Street Financial Group's 13F filing for Q2 2026, filed 14 Jul 2026.